These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32179045)

  • 1. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.
    Vandeputte MM; Cannaert A; Stove CP
    Arch Toxicol; 2020 Nov; 94(11):3819-3830. PubMed ID: 32734307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nanobody-based bio-assay using functional complementation of a split nanoluciferase to monitor Mu- opioid receptor activation.
    Vasudevan L; Stove CP
    Anal Bioanal Chem; 2020 Nov; 412(29):8015-8022. PubMed ID: 32926202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
    Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
    Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
    Yudin Y; Rohacs T
    Br J Pharmacol; 2019 Sep; 176(17):3110-3125. PubMed ID: 31074038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of β-arrestin-2 in short- and long-term opioid tolerance in the dorsal root ganglia.
    Muchhala KH; Jacob JC; Dewey WL; Akbarali HI
    Eur J Pharmacol; 2021 May; 899():174007. PubMed ID: 33705801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
    Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies.
    Miyano K; Manabe S; Komatsu A; Fujii Y; Mizobuchi Y; Uezono E; Ohshima K; Nonaka M; Kuroda Y; Narita M; Uezono Y
    Curr Top Med Chem; 2020; 20(31):2822-2829. PubMed ID: 33115393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.
    Chen XT; Pitis P; Liu G; Yuan C; Gotchev D; Cowan CL; Rominger DH; Koblish M; Dewire SM; Crombie AL; Violin JD; Yamashita DS
    J Med Chem; 2013 Oct; 56(20):8019-31. PubMed ID: 24063433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.
    Zhao Z; Huang T; Li J
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.
    Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX
    Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.
    Altarifi AA; David B; Muchhala KH; Blough BE; Akbarali H; Negus SS
    J Psychopharmacol; 2017 Jun; 31(6):730-739. PubMed ID: 28142305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
    Jiang X; Li S; Zhang H; Wang LL
    Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
    Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
    Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
    Mafi A; Kim SK; Goddard WA
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.
    Gillis A; Gondin AB; Kliewer A; Sanchez J; Lim HD; Alamein C; Manandhar P; Santiago M; Fritzwanker S; Schmiedel F; Katte TA; Reekie T; Grimsey NL; Kassiou M; Kellam B; Krasel C; Halls ML; Connor M; Lane JR; Schulz S; Christie MJ; Canals M
    Sci Signal; 2020 Mar; 13(625):. PubMed ID: 32234959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of
    Kapoor A; Provasi D; Filizola M
    Mol Pharmacol; 2020 Oct; 98(4):475-486. PubMed ID: 32680919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists.
    Stahl EL; Schmid CL; Acevedo-Canabal A; Read C; Grim TW; Kennedy NM; Bannister TD; Bohn LM
    Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of biased agonism at the A
    Pottie E; Tosh DK; Gao ZG; Jacobson KA; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113934. PubMed ID: 32224136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.